Cargando…

RNA Interference Therapy With ARC‐520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection

BACKGROUND AND AIMS: ARC‐520, the first an RNA interference (RNAi) therapeutic, was designed to reduce all RNA transcripts derived from covalently closed circular DNA, leading to a reduction in viral antigens and hepatitis B virus (HBV) DNA. APPROACH AND RESULTS: We aimed to evaluate the depth of he...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yuen, Man‐Fung, Schiefke, Ingolf, Yoon, Jung‐Hwan, Ahn, Sang Hoon, Heo, Jeong, Kim, Ju Hyun, Lik Yuen Chan, Henry, Yoon, Ki Tae, Klinker, Hartwig, Manns, Michael, Petersen, Joerg, Schluep, Thomas, Hamilton, James, Given, Bruce D., Ferrari, Carlo, Lai, Ching‐Lung, Locarnini, Stephen A., Gish, Robert G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496196/ https://www.ncbi.nlm.nih.gov/pubmed/31654573 http://dx.doi.org/10.1002/hep.31008

Ejemplares similares

Safety, Tolerability, and Pharmacokinetics of ARC‐520 Injection, an RNA Interference‐Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers
por: Schluep, Thomas, et al.
Publicado: (2016)

Origins and Evolution of the Primate Hepatitis B Virus
por: Locarnini, Stephen A., et al.
Publicado: (2021)

New Biomarkers of Chronic Hepatitis B
por: Mak, Lung-Yi, et al.
Publicado: (2019)

RNA Interference Therapy for Chronic Hepatitis B Predicts the Importance of Addressing Viral Integration When Developing Novel Cure Strategies
por: Wooddell, Christine I., et al.
Publicado: (2021)

Serum hepatitis B surface antigen (HBsAg) kinetics in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B
por: Seto, Wai-Kay, et al.
Publicado: (2012)

High Hepatitis B Surface Antigen Levels Predict Insignificant Fibrosis in Hepatitis B e Antigen Positive Chronic Hepatitis B
por: Seto, Wai-Kay, et al.
Publicado: (2012)

RNA interference as a novel treatment strategy for chronic hepatitis B infection
por: Hui, Rex Wan-Hin, et al.
Publicado: (2022)

Unresolved issues of immune tolerance in chronic hepatitis B
por: Lee, Hye Won, et al.
Publicado: (2020)

The use of transient elastography in the management of chronic hepatitis B
por: Fung, James, et al.
Publicado: (2011)

Entecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma
por: Mak, Lung-Yi, et al.
Publicado: (2020)

Hepatitis B virus X protein accelerates hepatocarcinogenesis with partner survivin through modulating miR-520b and HBXIP
por: Zhang, Weiying, et al.
Publicado: (2014)

Novel Antivirals in Clinical Development for Chronic Hepatitis B Infection
por: Mak, Lung-Yi, et al.
Publicado: (2021)

Update on the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Virus Infection
por: Hsu, Axel, et al.
Publicado: (2011)

Long-term Hepatitis B Surface Antigen Profile and Seroclearance after Severe Acute Flares of Chronic Hepatitis B
por: Hui, Ka-Yin, et al.
Publicado: (2023)

The Role of Steatosis in HBsAg Seroclearance for Patients with Chronic Hepatitis B Infection: Fact or Fiction?
por: Fung, James, et al.
Publicado: (2012)

Secreted hepatitis B virus splice variants differ by HBV genotype and across phases of chronic hepatitis B infection
por: Maslac, Olivia, et al.
Publicado: (2022)

The role of different viral biomarkers on the management of chronic hepatitis B
por: Mak, Lung-Yi, et al.
Publicado: (2023)

Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety
por: Lam, Yuk-Fai, et al.
Publicado: (2011)

Hepatitis B virus reactivation in seronegative occult hepatitis B patient receiving ibrutinib therapy
por: Lam, Lok-Ka, et al.
Publicado: (2023)

Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B
por: Mak, Lung-Yi, et al.
Publicado: (2023)

Sequence Variations of Full-Length Hepatitis B Virus Genomes in Chinese Patients with HBsAg-Negative Hepatitis B Infection
por: Huang, Fung-Yu, et al.
Publicado: (2014)

Hepatitis B Precore Protein: Pathogenic Potential and Therapeutic Promise
por: Walsh, Renae, et al.
Publicado: (2012)

A simple and inexpensive point-of-care test for hepatitis B surface antigen detection: serological and molecular evaluation
por: Gish, R G, et al.
Publicado: (2014)

Evolutionary Changes of Hepatitis B Virus Pre-S Mutations Prior to Development of Hepatocellular Carcinoma
por: Zhang, An-Ye, et al.
Publicado: (2015)

Reduction of liver stiffness following resolution of acute flares of chronic hepatitis B
por: Fung, James, et al.
Publicado: (2010)

Immunosuppression in Patients with Chronic Hepatitis B
por: Seetharam, Anil, et al.
Publicado: (2014)

Drugs in Development for Hepatitis B
por: Dawood, Altaf, et al.
Publicado: (2017)

Artificial Neural Network Accurately Predicts Hepatitis B Surface Antigen Seroclearance
por: Zheng, Ming-Hua, et al.
Publicado: (2014)

Complex genetic encoding of the hepatitis B virus on-drug persistence
por: Thai, Hong, et al.
Publicado: (2020)

A Large Population Histology Study Showing the Lack of Association between ALT Elevation and Significant Fibrosis in Chronic Hepatitis B
por: Seto, Wai-Kay, et al.
Publicado: (2012)

Rebound of HBV DNA after cessation of nucleos/tide analogues in chronic hepatitis B patients with undetectable covalently closed
por: Lai, Ching-Lung, et al.
Publicado: (2020)

First-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patients
por: Mak, Lung-Yi, et al.
Publicado: (2021)

Role of HLA-DP Polymorphisms on Chronicity and Disease Activity of Hepatitis B Infection in Southern Chinese
por: Wong, Danny Ka-Ho, et al.
Publicado: (2013)

Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog
por: Hui, Vicki Wing-Ki, et al.
Publicado: (2021)

Entecavir vs Tenofovir in Hepatocellular Carcinoma Prevention in Chronic Hepatitis B Infection: A Systematic Review and Meta-Analysis
por: Cheung, Ka Shing, et al.
Publicado: (2020)

This is hepatitis – it is closer than you think
por: Fung, James, et al.
Publicado: (2012)

Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients
por: Mak, Lung-Yi, et al.
Publicado: (2019)

Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay
por: Seto, Wai-Kay, et al.
Publicado: (2012)

Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection
por: Mak, Lung-Yi, et al.
Publicado: (2018)

Tumor suppressive role of mitochondrial sirtuin 4 in induction of G2/M cell cycle arrest and apoptosis in hepatitis B virus-related hepatocellular carcinoma
por: Huang, Fung-Yu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ropcsnn67dtdh94cgvlu721jqe